(AOF) – Eli Lilly is expected to rise in the pre-market on Wall Street after announcing that its flagship anti-diabetes and anti-obesity molecule tirzepatide (marketed under the name Mounjaro and Zepbound) had given positive results against Obstructive sleep apnea (OSA). The group announces that it has submitted its molecule to the FDA for approval for this indication, before contacting other health authorities around the world “in the coming weeks”. Specialist in devices against respiratory diseases, Resmed is expected to decline by 10%.